Production (Stage)
Ondine Biomedical Inc.
OBIMF
$0.14
$0.00392.87%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 425.10K | 436.20K | 313.90K | 318.60K | 284.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 425.10K | 436.20K | 313.90K | 318.60K | 284.80K |
| Cost of Revenue | 142.20K | 145.90K | 120.60K | 122.40K | 118.70K |
| Gross Profit | 282.90K | 290.30K | 193.30K | 196.20K | 166.10K |
| SG&A Expenses | 2.22M | 2.28M | 1.75M | 1.77M | 1.47M |
| Depreciation & Amortization | 93.90K | 96.40K | 99.40K | 100.90K | 101.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.57M | 4.69M | 3.18M | 3.22M | 2.77M |
| Operating Income | -4.15M | -4.26M | -2.86M | -2.90M | -2.49M |
| Income Before Tax | -4.05M | -4.16M | -2.84M | -2.88M | -2.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.05M | -4.16M | -2.84M | -2.88M | -2.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.05M | -4.16M | -2.84M | -2.88M | -2.39M |
| EBIT | -4.15M | -4.26M | -2.86M | -2.90M | -2.49M |
| EBITDA | -4.11M | -4.22M | -2.83M | -2.87M | -2.46M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 307.73M | 307.73M | 241.47M | 241.47M | 199.51M |
| Average Diluted Shares Outstanding | 307.73M | 307.73M | 241.47M | 241.47M | 199.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |